Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

RGNX

Regenxbio Inc

Apr 19 • 12:57PM ET

15.47

Dollar change -0.64
Percentage change -3.97	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IJR VTI VB IWM VBK VXF IWN IBB IJS VIOO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-6.03	Insider Own	9.41%	Shs Outstand	48.99M	Perf Week	-14.48%
Market Cap	757.88M	Forward P/E	-	EPS next Y	-2.06	Insider Trans	-3.46%	Shs Float	44.38M	Perf Month	-31.27%
Income	-263.49M	PEG	-	EPS next Q	-1.26	Inst Own	79.23%	Short Float	8.89%	Perf Quarter	12.84%
Sales	90.24M	P/S	8.40	EPS this Y	31.73%	Inst Trans	-3.02%	Short Ratio	5.35	Perf Half Y	-3.19%
Book/sh	7.08	P/B	2.19	EPS next Y	49.94%	ROA	-37.45%	Short Interest	3.95M	Perf Year	-19.39%
Cash/sh	5.62	P/C	2.75	EPS next 5Y	13.60%	ROE	-63.65%	52W Range	11.83 - 28.80	Perf YTD	-13.82%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-66.88%	52W High	-46.28%	Beta	1.37
Dividend TTM	-	Quick Ratio	2.57	Sales past 5Y	72.63%	Gross Margin	39.57%	52W Low	30.77%	ATR (14)	1.17
Dividend Ex-Date	-	Current Ratio	2.57	EPS Y/Y TTM	7.24%	Oper. Margin	-297.12%	RSI (14)	23.71	Volatility	5.92% 5.39%
Employees	344	Debt/Eq	0.29	Sales Y/Y TTM	-19.94%	Profit Margin	-291.99%	Recom	1.42	Target Price	39.83
Option/Short	Yes / Yes	LT Debt/Eq	0.26	EPS Q/Q	-3.25%	Payout	-	Rel Volume	0.48	Prev Close	16.11
Sales Surprise	-34.69%	EPS Surprise	-12.57%	Sales Q/Q	-29.13%	Earnings	Feb 27 AMC	Avg Volume	737.15K	Price	15.47
SMA20	-21.47%	SMA50	-22.06%	SMA200	-13.58%	Trades		Volume	197,942	Change	-3.97%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-24	Initiated	H.C. Wainwright	Buy	$36
Mar-08-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$20 → $35
Mar-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$37
Feb-21-24	Resumed	Raymond James	Outperform	$45
Nov-01-23	Initiated	Stifel	Buy	$35
Jun-02-23	Initiated	Robert W. Baird	Outperform	$42
Jun-23-22	Initiated	Berenberg	Buy	$61
Dec-15-21	Initiated	Wedbush	Neutral	$29
Oct-19-21	Resumed	Morgan Stanley	Overweight	$62 → $50
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy	$60
Dec-16-20	Initiated	UBS	Buy	$57
Jun-25-20	Resumed	BofA/Merrill	Buy	$9
Jun-25-20	Resumed	BofA/Merrill	Buy	$60
May-13-20	Initiated	RBC Capital Mkts	Sector Perform	$42
Aug-20-19	Upgrade	SVB Leerink	Underperform → Mkt Perform	$38 → $37
Jun-18-19	Reiterated	Chardan Capital Markets	Buy	$145 → $150
Jun-14-19	Resumed	Raymond James	Outperform
Jun-05-19	Reiterated	Chardan Capital Markets	Buy	$127.50 → $145
Feb-25-19	Upgrade	Evercore ISI	In-line → Outperform
Feb-05-19	Upgrade	Raymond James	Outperform → Strong Buy	$94

Show Previous Ratings

Mar-28-24 01:09PM	REGENXBIO Sees Positive Results For Macular Degeneration Therapy (Exec Edge) -5.00%
07:05AM	REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD (PR Newswire)
Mar-27-24 04:05PM	REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days (PR Newswire)
Mar-18-24 07:00PM	Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares (GuruFocus.com)
Mar-13-24 08:00AM	Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? (Motley Fool)
07:05AM	Loading…
Mar-11-24 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Mar-08-24 01:29AM	Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares (GuruFocus.com)
Mar-06-24 11:20PM	REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants (PR Newswire)
04:10PM	REGENXBIO Announces Proposed Public Offering of Common Stock (PR Newswire)
11:33AM	REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study (Zacks)
03:01AM	Regenxbio data suggest niche in Duchenne gene therapy (BioPharma Dive)
Mar-05-24 07:05AM	REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE TRIAL (PR Newswire) +15.22%
Feb-29-24 04:57PM	REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE Trial (PR Newswire) -12.36%
Feb-28-24 11:05AM	Q4 2023 Regenxbio Inc Earnings Call (Thomson Reuters StreetEvents)
09:36AM	REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:35PM	Loading…
Feb-27-24 05:35PM	Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +9.16%
04:41PM	Regenxbio Inc (RGNX) Reports Full Year 2023 Financial Results and Operational Highlights (GuruFocus.com)
04:32PM	Regenxbio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights (PR Newswire)
Feb-21-24 07:05AM	REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights (PR Newswire)
Feb-17-24 12:07AM	Regenxbio Inc President and CEO Kenneth Mills Sells 15,000 Shares (GuruFocus.com)
Feb-08-24 09:36AM	REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up (Zacks) +11.81%
04:50AM	Strength Seen in Regenxbio (RGNX): Can Its 11.7% Jump Turn into More Strength? (Zacks)
Feb-07-24 11:40AM	REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint (PR Newswire) +11.65%
07:05AM	REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE Trial (PR Newswire)
Jan-31-24 07:05AM	REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024 (PR Newswire)
Jan-18-24 09:01PM	Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares (GuruFocus.com)
Jan-16-24 02:47PM	REGENXBIO Announces Positive Interim Data from Phase II AAVIATE Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery (PR Newswire)
Jan-10-24 07:05AM	REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting (PR Newswire)
Jan-09-24 06:20PM	Down -25.53% in 4 Weeks, Here's Why You Should You Buy the Dip in Regenxbio (RGNX) (Zacks)
07:05AM	Loading…
Jan-08-24 07:05AM	U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV Technology Patent Infringement Lawsuit (PR Newswire) -12.22%
Dec-22-23 09:01AM	Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares (GuruFocus.com)
Nov-29-23 07:05AM	REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE Trial (PR Newswire)
Nov-16-23 09:55AM	Wall Street Analysts Believe Regenxbio (RGNX) Could Rally 95.61%: Here's is How to Trade (Zacks)
Nov-09-23 04:46PM	REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:37AM	'Difficult, but necessary, steps': SQZ lays off 80% of staff, Regenxbio cuts 15% (FierceBiotech.com)
Nov-08-23 04:42PM	Regenxbio: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results (PR Newswire)
Nov-07-23 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-03-23 06:53PM	REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery (PR Newswire) +8.03%
Nov-01-23 07:05AM	REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights (PR Newswire) +10.09%
Oct-30-23 07:05AM	REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting (PR Newswire)
Oct-05-23 07:05AM	REGENXBIO to Participate in the Jefferies CNS/Neuro Summit (PR Newswire)
Oct-03-23 04:05PM	REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society (PR Newswire)
Sep-26-23 07:05AM	REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society (PR Newswire)
Sep-05-23 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-30-23 07:05AM	Initial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium (PR Newswire)
Aug-23-23 04:05PM	REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 (PR Newswire)
Aug-02-23 05:55PM	Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:41PM	Regenxbio: Q2 Earnings Snapshot (AP Finance)
04:05PM	REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights (PR Newswire)
Aug-01-23 04:05PM	REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference (PR Newswire)
Jul-26-23 07:05AM	REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights (PR Newswire)
Jul-24-23 04:05PM	REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting (PR Newswire)
Jul-11-23 07:05AM	REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023 (PR Newswire)
Jul-01-23 10:09AM	Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price (Simply Wall St.)
Jun-27-23 07:05AM	REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates (PR Newswire) +6.89%
Jun-21-23 08:00PM	RGNX: Lowering target price to $25.00 (Argus Research)
Jun-20-23 08:00AM	REGENXBIO and University of Pennsylvania File NAV® Technology Patent Infringement Lawsuit (PR Newswire)
Jun-04-23 09:15AM	Even after rising 8.4% this past week, REGENXBIO (NASDAQ:RGNX) shareholders are still down 66% over the past five years (Simply Wall St.)
Jun-01-23 07:05AM	REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference (PR Newswire) +7.72%
May-23-23 07:05AM	REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome (PR Newswire)
May-22-23 07:05AM	REGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023 (PR Newswire)
May-16-23 05:52PM	REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio (PR Newswire) -9.17%
May-08-23 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
06:02AM	REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are More Bearish Than They Used To Be (Simply Wall St.)
May-04-23 06:44AM	Q1 2023 Regenxbio Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 05:55PM	Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:47PM	Regenxbio: Q1 Earnings Snapshot (AP Finance)
04:05PM	REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights (PR Newswire)
May-02-23 04:53PM	REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting (PR Newswire)
Apr-26-23 08:00PM	RGNX: Lowering target price to $24.00 (Argus Research)
04:05PM	REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational Highlights (PR Newswire)
Apr-18-23 07:05AM	REGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (PR Newswire)
Apr-15-23 08:20AM	Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now? (Motley Fool)
08:12AM	Here's Why We're Not Too Worried About REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation (Simply Wall St.)
Apr-11-23 07:05AM	REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy (PR Newswire)
Mar-08-23 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Mar-05-23 07:19AM	Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers (Simply Wall St.)
Mar-02-23 05:51AM	REGENXBIO Full Year 2022 Earnings: Revenues Disappoint (Simply Wall St.)
Feb-28-23 08:25PM	Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights (PR Newswire)
Feb-24-23 09:20AM	Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium (PR Newswire)
Feb-22-23 03:00PM	Additional Positive Interim Data from Phase I/II/III CAMPSIITE Trial of REGENXBIO's RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM (PR Newswire)
10:00AM	Will Intra-Cellular Therapies (ITCI) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-21-23 07:05AM	REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights (PR Newswire)
Feb-17-23 07:05AM	REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium 2023 (PR Newswire)
Feb-11-23 08:40AM	REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress Manufacturing Platform Process (PR Newswire)
Feb-08-23 07:05AM	REGENXBIO Announces Presentation at the Virtual SVB Securities Global Biopharma Conference (PR Newswire)
Feb-06-23 07:05AM	REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 Conference (PR Newswire)
Jan-26-23 08:00AM	Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDAs Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy (GlobeNewswire)
Jan-23-23 11:46AM	Rockville biotech RegenxBio launches clinical trial in muscular dystrophy (American City Business Journals)
07:05AM	REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients (PR Newswire)
Jan-10-23 01:58PM	Rockvilles RegenxBio promotes 2 senior executives as it enters next phase of growth (American City Business Journals)
Jan-09-23 04:01PM	REGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONS (PR Newswire)
Jan-03-23 07:05AM	REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-21-22 07:05AM	REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease (PR Newswire)
Dec-08-22 07:05AM	REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I (PR Newswire)
Dec-03-22 08:26AM	REGENXBIO (NASDAQ:RGNX) adds US$71m to market cap in the past 7 days, though investors from three years ago are still down 46% (Simply Wall St.)
Nov-30-22 02:36PM	Rockville's RegenxBio lays out potential path to market for its first gene therapy treatments (American City Business Journals) +5.94%

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mills Kenneth T.	President and CEO	Apr 15 '24	Option Exercise	3.76	15,000	56,400	423,035	Apr 17 05:05 PM
Mills Kenneth T.	President and CEO	Apr 15 '24	Sale	18.19	15,000	272,871	408,035	Apr 17 05:05 PM
Vasista Vittal	Chief Financial Officer	Mar 19 '24	Option Exercise	3.76	20,041	75,354	246,534	Mar 21 05:20 PM
Mills Kenneth T.	President and CEO	Mar 14 '24	Option Exercise	3.76	15,000	56,400	423,035	Mar 18 05:03 PM
Mills Kenneth T.	President and CEO	Mar 14 '24	Sale	21.86	15,000	327,942	408,035	Mar 18 05:03 PM
PAKOLA STEVE	Chief Medical Officer	Mar 05 '24	Option Exercise	22.25	12,878	286,536	120,070	Mar 07 06:05 PM
PAKOLA STEVE	Chief Medical Officer	Mar 05 '24	Sale	28.36	12,878	365,220	107,192	Mar 07 06:05 PM
Mills Kenneth T.	President and CEO	Feb 14 '24	Option Exercise	3.76	15,000	56,400	423,035	Feb 16 06:28 PM
Mills Kenneth T.	President and CEO	Feb 14 '24	Sale	16.76	15,000	251,349	408,035	Feb 16 06:28 PM
Mills Kenneth T.	President and CEO	Jan 16 '24	Option Exercise	3.76	45,000	169,200	453,035	Jan 18 06:39 PM
Mills Kenneth T.	President and CEO	Jan 16 '24	Sale	15.18	45,000	682,992	408,035	Jan 18 06:39 PM
PAKOLA STEVE	Chief Medical Officer	Jan 03 '24	Sale	17.39	17,237	299,789	107,192	Jan 04 04:23 PM
Mills Kenneth T.	President and CEO	Dec 19 '23	Option Exercise	3.66	45,000	164,835	400,289	Dec 21 01:38 PM
Mills Kenneth T.	President and CEO	Dec 19 '23	Sale	19.68	45,000	885,825	355,289	Dec 21 01:38 PM
Vasista Vittal	Chief Financial Officer	May 31 '23	Option Exercise	0.85	35,000	29,750	215,001	Jun 02 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGNX

Regenxbio Inc

Upgrade your FINVIZ experience